About ImmunoGen Company
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.
ImmunoGen Bags Priority Review for Full Approval of Ovarian Cancer Drug
FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE (Mirvetuximab Soravtansine-Gynx) in Platinum-Resistant Ovarian Cancer
ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has filed
Analysts Conflicted on These Healthcare Names: Natera (NTRA), ImmunoGen (IMGN) and Pfizer (PFE)